FIGURE 4 from Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer
Year: 2023
Type: other
Abstract: In silico trial predictions of multiple palbociclib treatment administration schedules in combination with fulvestrant. For −DOX cells (A) and for +DOX cells (B), The panels show the box plots for the number of cells at day 100. The p-values were computed using the Wilcoxon test. In each panel, we only show the largest two p-values. The p-values not shown in the panels, for the rest of pairs of treatment schedules, are all smaller than 1e − 15 in A and 1e − 13 in B. For −DOX cells (C) and for +DOX cells (D), The panels show the waterfall charts for 150 random samples from the group of 1,500 simulations in descending order of cell number at day 100. For −DOX cells (E) and for +DOX cells (F), The panels show the predictions of in silico cell growth trajectories by taking the ratio of each schedule to the standard schedule (daily, 125 mg, 3 weeks on, 1 week off). The shaded area corresponds to the 95% credible interval of the posterior predictive values.
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4388729682